LATEST ALERTS
Canadian advocates for therapeutic access to psilocybin are ramping up their efforts to get the federal government to grant exemptions to the country’s drug laws so patients and healthcare providers can legally access the drug
A measure to allow the use of psychedelics in Colorado is a major step – but supporters worry it could lead to the sort of bad experience that would set back the progress of legalisation
It is not only cannabis that is attracting what might be thought unexpected investment and support from traditionally conservative, right-wing supporters and lobbyists in the US
Drug legalisation as an issue truly does bring together some strange bedfellows – like the Navajo Nation and drug prohibitionists
As debate over the legalisation of recreational cannabis involves a growing number of European countries, the commercial demand for legal psychoactive alternatives to controlled cannabinoid variants is on the rise
A new conceptual inhaler designed around the idea of controlled microdosing could eventually lead to a product capable of administering precise amounts of active ingredients such as CBD, nicotine or even psychedelics
The US Drug Enforcement Administration (DEA) has withdrawn its proposal to effectively ban five psychedelic compounds after receiving significant opposition from the research and advocacy community
Psychedelics are having another moment in the spotlight. But is the heightened awareness just hype, or have these once-taboo substances been permanently rehabilitated?
Biotechnology firm Awakn Life Sciences has secured UK government funding to accelerate the route to the UK and US markets for its proprietary ketamine-assisted therapy, which is designed to treat alcohol use disorder
As the first federally approved psychedelics clinical trial begins in the US, there is broad but not total agreement among official bodies over legalising research into hallucinogenic substances
Strangely, Brexit and then the Covid-19 pandemic have combined to create ideal conditions for the UK to potentially become a leader in psychedelics research
CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
